NORTHWOOD, OHIO, USA – Oct. 15, 2012 – NAMSA, the world’s leading medical device research organization, continues its steady growth with an expansion of its state-of-the-art laboratories in Lyon, France.
Increased demand for NAMSA’s biocompatibility and histopathology services has led the company to invest in building an additional 12,000 square feet for its facility, which increases its capacity in Lyon by roughly 30 percent.
“We are growing quickly to support the needs of our customers,” said Dr. Jean Pierre Boutrand, general manager of NAMSA in Lyon.“This expansion will allow us to add staff and help meet increased demand for efficient testing and reporting during the medical device development and testing process.”
NAMSA employs a number of board-certified pathologists around the world to offer clients timely collection and processing of tissue samples, custom sample preparation and sectioning, specialized tissue-implant processing and other services.
“The medical device research, regulatory approval and commercialization process is continuously taking longer and costing more, driving the need for efficiencies wherever possible and we are very focused on that,” said Boutrand.
With recent acquisitions and expansions, NAMSA is well positioned as a fully integrated provider for medical device manufacturers, having breadth and depth in consulting, non-clinical and clinical services. NAMSA has expertise in cardiovascular, orthopedic, ocular, neurologic, gastroenterologic, urologic, combination product and related medical devices and can help manufacturers accelerate the process of bringing their devices to market.
NAMSA’s newly expanded space, which also includes meeting rooms and offices, will open in mid-December.
NAMSA (www.namsa.com) is a global medical device research organization providing a comprehensive range of services to prove efficacy, non-clinical and clinical safety of medical devices, IVDs and combination products. For more than 45 years, NAMSA clients have utilized its testing and consulting services to bring safe and effective therapies to market.